SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
+3.76%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$151M
AUM Growth
+$151M
(+18%)
Cap. Flow
+$26.9M
Cap. Flow
% of AUM
17.79%
Top 10 Holdings %
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$2.19M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$2.16M |
| 3 |
Replimune Group
REPL
|
$2.15M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$2.15M |
| 5 |
Solid Biosciences
SLDB
|
$2.05M |
Top Sells
| 1 |
Medtronic
MDT
|
$2.14M |
| 2 |
Gilead Sciences
GILD
|
$1.37M |
| 3 |
Tenet Healthcare
THC
|
$1.21M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$1.12M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$994K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCAX
26
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $1.87M | 1.24% | +201,395 | New | +$1.87M |
|
27
Pfizer
PFE
$141B
| $1.87M | 1.23% | 77,150 +17,500 | +29% | +$424K |
|
|
ONC
28
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.87M | 1.23% | 7,716 +4,789 | +164% | +$1.16M |
|
29
Kura Oncology
KURA
$686M
| $1.87M | 1.23% | +323,572 | New | +$1.87M |
|
30
Tourmaline Bio
TRML
$601M
| $1.86M | 1.23% | +116,510 | New | +$1.86M |
|
31
AnaptysBio
ANAB
$569M
| $1.86M | 1.23% | +83,900 | New | +$1.86M |
|
32
Instil Bio
TIL
$182M
| $1.8M | 1.19% | +86,220 | New | +$1.8M |
|
33
Immatics
IMTX
$619M
| $1.79M | 1.18% | +332,270 | New | +$1.79M |
|
34
BioNTech
BNTX
$24B
| $1.72M | 1.14% | 16,160 -1,015 | -6% | -$108K |
|
35
Merck
MRK
$210B
| $1.67M | 1.1% | 20,900 -6,000 | -22% | -$478K |
|
36
Thermo Fisher Scientific
TMO
$186B
| $1.58M | 1.04% | 3,900 +650 | +20% | +$264K |
|
37
Stryker
SYK
$150B
| $1.55M | 1.02% | 3,900 -2,200 | -36% | -$872K |
|
38
Insmed
INSM
$28.8B
| $1.5M | 0.99% | 14,880 -350 | -2% | -$35.2K |
|
39
Regeneron Pharmaceuticals
REGN
$61.5B
| $1.46M | 0.96% | 2,773 | – | – |
|
40
Summit Therapeutics
SMMT
$17.6B
| $1.39M | 0.92% | 65,220 -4,020 | -6% | -$85.5K |
|
41
AstraZeneca
AZN
$248B
| $1.3M | 0.86% | 18,640 -150 | -0.8% | -$10.5K |
|
42
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.29M | 0.85% | 23,530 | – | – |
|
43
Edwards Lifesciences
EW
$47.8B
| $1.17M | 0.77% | +15,000 | New | +$1.17M |
|
44
DexCom
DXCM
$29.5B
| $1.15M | 0.76% | 13,200 -1,800 | -12% | -$157K |
|
45
ARS Pharmaceuticals
SPRY
$1.15B
| $1.15M | 0.76% | 65,785 -34,420 | -34% | -$601K |
|
46
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.08M | 0.72% | 3,323 -1,882 | -36% | -$614K |
|
47
Structure Therapeutics
GPCR
$1.11B
| $1.07M | 0.7% | 51,369 +17,674 | +52% | +$367K |
|
48
Vera Therapeutics
VERA
$1.38B
| $976K | 0.64% | 41,418 +13,070 | +46% | +$308K |
|
49
Merus
MRUS
$4.98B
| $825K | 0.54% | +15,675 | New | +$825K |
|
50
Globus Medical
GMED
$8.27B
| $797K | 0.53% | +13,500 | New | +$797K |
|